Drugs / E7766
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04144140 | Feb 2020 → Jul 2022 | cancer, lymphoma | Eisai Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04109092 | Feb 2020 → Sep 2022 | urinary bladder neoplasm | Eisai Inc. | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E7766 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04109092 ↗ |
| Action | Activate | “STING Agonist E7766” NCT04144140 ↗ |
| Modality | Other / unclassified | “STING Agonist E7766” NCT04144140 ↗ |
| Route | Other | “E7766, solution, intravesically.” NCT04109092 ↗ |